View Author
patient arthritis treatment disease etanercept idiopathic arthritis response agent trial month idiopathic study rheum rheumatology chapter disease activity jia patients activity factor psoriatic skin lesions ann rheum dis children adalimumab paediatric acrpedi course follow-up 15 months safety anakinra psoriatic score acrpedi 30 response dmard category methotrexate efficacy infliximab comparison result remission therapy arthritis rheum range event 3 months 6 months duration group 8/14 etanercept treatment number biologic criteria femke h.m randomized flare joint hospital effectiveness onset otten table prince assessment characteristic placebo outcome treatment response abatacept difference withdrawal rheumatol poly-articular subtype tocilizumab tnf-alpha analysis van suijlekom-smit pattern
3 Most Recent Publications
|
A decade of biologic treatment observation in juvenile idiopathic arthritis: Lessons learned from the Dutch ABC Register
(Doctoral Thesis)
Otten, M.H. |
2012-06-01
|
|
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: Are they effective?
(Article)
Otten, M.H. Prince, F.H.M. Armbrust, W. Dolman, K.M. Wulffraat, N.M. Suijlekom-Smit, L.W.A. van Cate, R. ten Rossum, M.A.J. van Twilt, M. Hoppenreijs, E. Koopman-Keemink, Y. Oranje, A.P. Waard-Van der Spek, F.B. de Gorter, S.L. |
2011-02-01
|
|
Disease activity patterns in juvenile systemic lupus erythematosus and its relation to early aggressive treatment
(Article)
Otten, M.H. Cransberg, K. Rossum, M.A.J. van Groothoff, J. Kist-Van Holthe, J.E. Cate, R. ten Suijlekom-Smit, L.W.A. van |
2010-11-01
|
